• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Exercise may cut breast cancer risk, study finds
ConclusionThis large study has shown that increased exercise is associated with a reduced risk of breast cancer for postmenopausal women. Strengths of the study include the large number of women and that self-reports of breast cancer were verified by a pathology report in 94% of cases.However, as the authors point out, a limitation of this study is that it was conducted on a group of teachers who were mainly of a healthy weight. This means the results may not be applicable to women of a different weight with different occupations, including more or less sedentary jobs.The study also relied on self-reported exercise levels,...
Source: NHS News Feed - August 11, 2014 Category: Consumer Health News Tags: Cancer Lifestyle/exercise Source Type: news